MX375765B - Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales. - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales.

Info

Publication number
MX375765B
MX375765B MX2017007567A MX2017007567A MX375765B MX 375765 B MX375765 B MX 375765B MX 2017007567 A MX2017007567 A MX 2017007567A MX 2017007567 A MX2017007567 A MX 2017007567A MX 375765 B MX375765 B MX 375765B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
gastrointestinal diseases
sucralfate
ranitidine
treatment
Prior art date
Application number
MX2017007567A
Other languages
English (en)
Other versions
MX2017007567A (es
Inventor
Jun Woo Lee
Young Ho Jo
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375765(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2017007567A publication Critical patent/MX2017007567A/es
Publication of MX375765B publication Critical patent/MX375765B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/245Bismuth; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica para el tratamiento de enfermedades gastrointestinales que comprende ranitidina, sucralfato y subcitrato de bismuto como componentes activos y un método de preparación de los mismos. De acuerdo con la presente invención, cuando se prepara un fármaco de combinación de ranitidina, sucralfato y subcitrato de bismuto, es posible hacer frente a un problema de higroscopicidad de ranitidina y aumentar la estabilidad de la formulación y disponibilidad biológica de fármacos por medio del control de los tamaños de partícula de sucralfato y subcitrato de bismuto.
MX2017007567A 2015-01-30 2016-01-28 Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales. MX375765B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (2)

Publication Number Publication Date
MX2017007567A MX2017007567A (es) 2017-10-19
MX375765B true MX375765B (es) 2025-03-07

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007567A MX375765B (es) 2015-01-30 2016-01-28 Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales.

Country Status (19)

Country Link
EP (1) EP3250199A4 (es)
JP (1) JP6419347B2 (es)
KR (2) KR101583452B1 (es)
CN (1) CN107205947B (es)
AR (1) AR105413A1 (es)
CL (1) CL2017001680A1 (es)
CO (1) CO2017006222A2 (es)
EA (1) EA032385B9 (es)
EC (1) ECSP17038599A (es)
GE (1) GEP20196941B (es)
MA (1) MA41432A (es)
MX (1) MX375765B (es)
MY (1) MY195824A (es)
PE (1) PE20171340A1 (es)
PH (1) PH12017550051A1 (es)
SA (1) SA517382016B1 (es)
TW (1) TWI635859B (es)
UA (1) UA116517C2 (es)
WO (1) WO2016122226A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
ATE213635T1 (de) * 1994-04-26 2002-03-15 Chugai Pharmaceutical Co Ltd Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
AU8354498A (en) * 1997-08-25 1999-03-16 Procter & Gamble Company, The Combined preparations for treating upper gastrointestinal tract distress
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
WO2010001930A1 (ja) * 2008-07-01 2010-01-07 ライオン株式会社 固形内服製剤
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
UA116517C2 (uk) 2018-03-26
JP6419347B2 (ja) 2018-11-07
PH12017550051A1 (en) 2018-01-29
SA517382016B1 (ar) 2021-03-18
CO2017006222A2 (es) 2017-09-20
AR105413A1 (es) 2017-10-04
CL2017001680A1 (es) 2018-01-12
MX2017007567A (es) 2017-10-19
CN107205947B (zh) 2020-05-22
JP2018503672A (ja) 2018-02-08
MY195824A (en) 2023-02-22
KR101583452B1 (ko) 2016-01-11
PE20171340A1 (es) 2017-09-13
KR20160094268A (ko) 2016-08-09
ECSP17038599A (es) 2017-09-29
TWI635859B (zh) 2018-09-21
EA201791458A1 (ru) 2017-11-30
WO2016122226A2 (en) 2016-08-04
EP3250199A2 (en) 2017-12-06
TW201639559A (zh) 2016-11-16
EP3250199A4 (en) 2018-08-08
KR101583452B9 (ko) 2022-05-02
CN107205947A (zh) 2017-09-26
BR112017013857A2 (pt) 2018-02-27
WO2016122226A3 (en) 2016-09-15
GEP20196941B (en) 2019-01-10
EA032385B1 (ru) 2019-05-31
EA032385B9 (ru) 2019-07-31
MA41432A (fr) 2017-12-05

Similar Documents

Publication Publication Date Title
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
CO2019004776A2 (es) Nuevos derivados de quinolina-3-carboxamida antihelmínticos
WO2014147611A8 (en) Quinolines derivatives as novel anticancer agents
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
IL261196B (en) A pharmaceutical preparation for the treatment of cancer, containing a polyphenol compound as an active ingredient
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
DK3604304T3 (da) Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme
WO2015001541A3 (en) Pharmaceutical film composition
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
MX375765B (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
EP3795170A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE

Legal Events

Date Code Title Description
FG Grant or registration